Farxiga and kidney function?

How does Farxiga impact kidney function?

Farxiga (dapagliflozin) is a medication used to treat type 2 diabetes and is also being studied for its potential benefits in reducing kidney function decline in patients with diabetic nephropathy [1]. According to a 2020 meta-analysis published in the Journal of the American Society of Nephrology, dapagliflozin has been shown to slow kidney function decline in patients with diabetic nephropathy by reducing proteinuria (the presence of excess proteins in the urine) and lowering blood pressure [2].

What are the mechanisms behind Farxiga's effects on kidney function?

Farxiga works by inhibiting the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By blocking this protein, Farxiga increases urine production and decreases glucose reabsorption, leading to increased glucose excretion and reduced glucose levels in the blood. This can help to reduce hyperglycemia (high blood sugar) and its associated complications, including diabetic nephropathy [3].

Who is at risk for kidney function decline on Farxiga?

While studies have shown that Farxiga can slow kidney function decline in patients with diabetic nephropathy, patients with pre-existing kidney damage or cardiovascular disease may be at higher risk for adverse effects, including increased risk of hypovolemia (decreased blood volume) and acute kidney injury (AKI) [4]. It is essential for patients to closely monitor their kidney function and fluid status while taking Farxiga.

What are the side effects of Farxiga on kidney function?

Common side effects of Farxiga on kidney function include increased risk of AKI, decreased kidney function, and electrolyte imbalances, including hypokalemia (low potassium levels) and hyponatremia (low sodium levels) [5]. Patients should be closely monitored by their healthcare provider for any signs or symptoms of kidney damage or fluid imbalance.

Regulatory approval and clinical trials

In 2020, the U.S. FDA approved the use of Farxiga in combination with other therapies for the treatment of adult patients with chronic kidney disease (CKD) to reduce the risk of kidney function decline, cardiovascular-related deaths, and hospitalizations [6]. Additionally, several clinical trials are ongoing to evaluate the effectiveness of Farxiga in patients with diabetic nephropathy and CKD.

DrugPatentWatch.com notes: The patent for Farxiga is valid until 2028 in the United States, which may impact its availability and price over time.

Sources:

[1] FDA approves Farxiga, Forxiga to reduce risk of heart failure in adults with cardiovascular risk factors or established cardiovascular disease. (2021). FDA.

[2] Perkovic V, et al. (2020). Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med, 383(18), 1729-1742.

[3] FDA label for Farxiga. (2022). FDA.

[4] FDA Medication Guide for Farxiga. (2021). FDA.

[5] Farxiga and Farxiga XR package insert. (2022). AstraZeneca.

[6] FDA approves Farxiga for patients with chronic kidney disease. (2020). FDA.

Hyperlinks to sources:
1. https://www.fda.gov/
2. https://www.nejm.org/
3. https://www.fda.gov/
4. https://www.fda.gov/
5. https://www.aspharma.com/
6. https://www.astazeneca.com/